As of 2024-12-14, the Intrinsic Value of Biomarin Pharmaceutical Inc (BMRN) is
16.56 USD. This Biomarin valuation is based on the model Discounted Cash Flows (Growth Exit 5Y).
With the current market price of 66.01 USD, the upside of Biomarin Pharmaceutical Inc is
-74.90%.
The range of the Intrinsic Value is 10.42 - 36.95 USD
16.56 USD
Intrinsic Value
Biomarin Intrinsic Value - Valuation Summary
|
Range |
Selected |
Upside |
| a |
| DCF (Growth 5y) |
10.42 - 36.95 |
16.56 |
-74.9% |
| DCF (Growth 10y) |
19.15 - 63.05 |
29.35 |
-55.5% |
| DCF (EBITDA 5y) |
32.87 - 37.14 |
34.56 |
-47.6% |
| DCF (EBITDA 10y) |
40.41 - 49.02 |
44.06 |
-33.2% |
| Fair Value |
42.28 - 42.28 |
42.28 |
-35.95% |
| P/E |
25.52 - 55.27 |
39.75 |
-39.8% |
| EV/EBITDA |
25.28 - 44.51 |
35.26 |
-46.6% |
| EPV |
2.81 - 3.96 |
3.39 |
-94.9% |
| DDM - Stable |
20.35 - 81.46 |
50.91 |
-22.9% |
| DDM - Multi |
24.02 - 74.31 |
36.25 |
-45.1% |
Biomarin Intrinsic Value - Key Valuation Metrics
| Market Cap (mil) |
12,580.19 |
| Beta |
0.39 |
| Outstanding shares (mil) |
190.58 |
| Enterprise Value (mil) |
12,881.15 |
| Market risk premium |
4.60% |
| Cost of Equity |
7.84% |
| Cost of Debt |
4.25% |
| WACC |
7.47% |